Investors.

In late 2011, AMPT raised funds in a Series A Financing Round from renowned international life science investors Boehringer Ingelheim Venture Fund and Novartis Venture Funds.

About the Boehringer Ingelheim Venture Fund (BIVF)
The BIVF was formed in March 2010 and invests in biotechnology and start-up companies that provide ground-breaking therapeutic approaches and medicinal technologies to help drive innovation in medical science. These may include - but are not limited to – novel technologies to address so far undruggable targets, new-generation vaccines and new biological entities, such as antibody-dependent oncolysis. Novel therapeutic targets and disease-related biomarkers, as well as new approaches in regenerative medicine, are an additional focus.
Boehringer-Ingelheim Venture Fund

 

About the Novartis Venture Funds (NVF)
NVF currently manages over $750 million in committed capital. NVF invests in companies which have the potential to change a core therapeutic field or explore new business areas that are critical to patient care. NVF primary interest is in the development of novel therapeutics and platforms as well as medical devices, diagnostics, and delivery systems. NVF invests for financial objectives at all stages, but prefers to invest in the early-stages of company development. With eight investment professionals, located in Basel, Switzerland and Cambridge, MA, the team has extensive experience in pharmaceutical R&D and venture capital.
Novartis Venture Funds